AzTrials
AzTrials

Aneurysm, BrainPRAEMIUMNCT04819074

Prediction of Outcomes After Surgery for Unruptured Intracranial Aneurysms

An observational study of Aneurysm, Brain, run by University of Zurich at 37 sites in 10 countries.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Accurate preoperative identification of patients at high risk for adverse outcomes would be clinically advantageous, as it would allow enhanced resource preparation, better surgical decision-making, enhanced patient education and informed consent, and potentially even modification of certain modifiable risk factors. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Aneurysm, Brain
What is being tested?
Microsurgery
Type of treatment
Surgery or procedure
How many people
4,000 participants
Where
37 sitesin 10 countries
Study dates
20 May 2021to 1 Oct 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: We will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study.

Who may be able to join

  • Adult patients (18 or older)
  • Undergone microsurgical treatment for unruptured intracranial aneurysm
  • Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus.
  • Treated from January 1st 2010 onwards

Who cannot join

  • No specific exclusion criteria

Trial locations and contacts

37 sites in 10 countries.

Victor Staartjes contact

+41 44 255 2660

praemium@usz.ch

37 sites in 10 countries

United States10 sites, 10 recruiting
  • Emory University Hospital

    Atlanta, Georgia, 30322

    Daniel Barrow

    Not yet recruiting
  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115

    Antonio Chiocca

    Not yet recruiting
  • University of Illinois

    Chicago, Illinois, 60612

    Fady Charbel

    Not yet recruiting
  • UCLA

    Los Angeles, California, 90095

    Linda Liau

    Not yet recruiting
  • University of Wisconsin

    Madison, Wisconsin, 53792

    Mustafa K Baskaya

    Not yet recruiting
  • North Shore University Hospital

    Manhasset, New York, 11030

    Amir Dehdashti

    Not yet recruiting
  • Barrow Neurological Institute

    Phoenix, Arizona, 85013

    Michael Lawton

    Not yet recruiting
  • Mayo Clinic

    Rochester, Minnesota, 55902

    Giuseppe Lanzino

    Not yet recruiting
  • UCSF

    San Francisco, California, 94143

    Mitchel S Berger

    Not yet recruiting
  • Stanford University

    Stanford, California, 94305

    Gary K Steinberg

    Not yet recruiting

Other trials in United States

Italy8 sites, 8 recruiting
  • University of Florence - Careggi

    Florence

    Alessandro Della Puppa

    Not yet recruiting
  • University of Genoa

    Genoa

    Gianluigi Zona

    Not yet recruiting
  • University of Messina

    Messina

    Antonino Germano

    Not yet recruiting
  • Carlo Besta

    Milan

    Paolo Ferroli

    Not yet recruiting
  • Padova University

    Padova

    Domenico D'Avella

    Not yet recruiting
  • Gemelli University Hospital

    Roma

    Alessandro Olivi

    Not yet recruiting
  • Sapienza University

    Roma

    Antonio Santoro

    Not yet recruiting
  • University of Verona

    Verona

    Giampietro Pinna

    Not yet recruiting

Other trials in Italy

Germany7 sites, 7 recruiting
  • Charité Univesitätsmedizin

    Berlin

    Peter Vajkoczy

    Not yet recruiting
  • University of Cologne

    Cologne

    Roland Goldbrunner

    Not yet recruiting
  • Dresden Uniklinikum

    Dresden

    Gabriele Schackert

    Not yet recruiting
  • Düsseldorf Universitätsmedizin

    Düsseldorf

    Daniel Hänggi

    Not yet recruiting
  • Frankfurt University

    Frankfurt

    Volker Seifert

    Not yet recruiting
  • Universitätsmedizin Göttingen

    Göttingen

    Veit Rohde

    Not yet recruiting
  • Unimedizin Mainz

    Mainz

    Florian Ringel

    Not yet recruiting

Other trials in Germany

Netherlands3 sites, 3 recruiting
  • Amsterdam UMC

    Amsterdam

    W. Peter Vandertop

    Not yet recruiting
  • Leiden University

    Leiden

    Wilco C Peul

    Not yet recruiting
  • UMC Utrecht

    Utrecht

    Albert van der Zwan

    Not yet recruiting

Other trials in Netherlands

Australia2 sites, 2 recruiting
  • Royal Melbourne Hospital

    Melbourne

    Kate Drummond

    Not yet recruiting
  • Macquarie University

    Sydney

    Antonio Di Ieva

    Not yet recruiting

Other trials in Australia

Austria2 sites, 2 recruiting
  • Innsbruck University

    Innsbruck

    Claudius Thomé

    Not yet recruiting
  • Linz Kepler Klinikum

    Linz

    Andreas Gruber

    Not yet recruiting

Other trials in Austria

Switzerland2 sites, 2 recruiting
  • Inselspital Bern

    Bern

    Andreas Raabe

    Not yet recruiting
  • University Hospital Zurich

    Zurich

    Victor Staartjes

    Giuseppe Esposito

    Recruiting

Other trials in Switzerland

Czechia1 site, 1 recruiting
  • Prague University

    Prague

    Vladimir Benes

    Not yet recruiting

Other trials in Czechia

Russia1 site, 1 recruiting
  • Burdenko Hospital

    Moscow

    Eliava Shalva

    Not yet recruiting

Other trials in Russia

Sweden1 site, 1 recruiting
  • Sahlgrenska Hospital

    Gothenburg

    Asgeir Jakola

    Not yet recruiting

Other trials in Sweden

About this study

Official title: The Prediction of Adverse Events After Microsurgery for Intracranial Unruptured Aneurysms (PRAEMIUM) Study

Accurate preoperative identification of patients at high risk for adverse outcomes would be clinically advantageous, as it would allow enhanced resource preparation, better surgical decision-making, enhanced patient education and informed consent, and potentially even modification of certain modifiable risk factors. The aim of the Prediction of adverse events after microsurgery for intracranial unruptured aneurysms (PRAEMIUM) study is therefore to develop and externally validate a clinically applicable, robust ML-based prediction tool based on multicenter data from a range of international centers.

Read the detailed description

Introduction Unruptured intracranial aneurysms (UIAs) are incidentally detected at an increasing rate, mostly owing to the rise in availability of non-invasive cranial imaging. Decision-making in UIAs is complex and requires consideration of many risk factors for aneurysm growth and rupture to balance the benefits and risks of treatment versus observation. This is due to: 1) the high morbidity and case fatality inherent to aneurysmal subarachnoid hemorrhage (SAH) 2) the relatively low rupture rate of unruptured aneurysms; 3) the potential morbidity and mortality rate associated with either microsurgical or endovascular treatment.

Some consistent risk factors for rupture have been identified, including involvement of the posterior circulation, larger diameter, higher age, and some specific populations such as Japanese and Finnish patients. Many other risk factors have been suggested based on varying levels of evidence. However, it is difficult to integrate this considerable number of factors into a single risk assessment and to present a clear clinical decision making algorithm to patients. A range of scoring systems have been developed and validated to approximate the risk of rupture (PHASES) and growth (ELAPSS) or to balance the risks and benefits of microsurgical treatment versus follow-up imaging directly (UIATS) by integrating some of these risk factors. Still, these scores are focused on predicting rupture events instead of neurological outcome. In addition, they usually are focused on solely one outcome, instead of providing a wide range of objective predictive analytics that may then improve shared decision-making.

Machine learning (ML) methods have been extraordinarily effective at integrating many clinical patient variables into one holistic risk prediction tailored to each patient. A previous pilot study has been carried out to assess the feasibility of predicting surgical outcomes after surgery for UIAs in a small single-center sample, and it was found that prediction was feasible with good performance metrics, and the most important factors to be included in such models were also identified. A robust, multicenter, externally validated prediction model or predictive score for surgical outcome after microsurgery for UIAs does not yet exist.

Methods Data will be collected by a range of international centers. Overall, the model will be built and publication will be compiled according to the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidelines.

Each center will collect their data either retrospectively, or from a prospective registry, or from a prospective registry supplemented by retrospectively collected variables. Data from patients operated from January 1st 2010 and onwards will be eligible for inclusion. Data collection should be completed, and deidentified data should be sent to the sponsor institution.

A standardized Excel spreadsheet will be provided by the sponsor. The data will be entered in standardized and anonymized form. This spreadsheet will only contain a study-specific patient number. The data set is anonymized source data that includes clinical data extracted from electronic health records (retrospectively or from a prospective registry of already existing data). The data will be anonymized upon entering them into the PRAEMIUM Excel spreadsheet, after which the patients will be numbered consecutively and there will be no way to trace the data back to individual patients. No identifiable data such as date of birth will be included. Whenever the PRAEMIUM Excel spreadsheet is transferred, it will be encrypted using a password and sent through a secure institutional e-mail server. The password will be sent in a separate e-mail. Some missing data is acceptable, but should be kept to a minimum (i.e. must be < 10%)

Endpoint Definitions Models will be developed for the following three endpoints at discharge: Poor neurological outcome (1), as well as presence of (2) new sensorimotor neurological deficits and (3) any complications (surgical or non-surgical). Neurological outcome was assessed by the modified Rankin scale (mRS), and a favorable neurological outcome was defined as mRS 0, 1, or 2. Complications will be assessed using the modified 2009 Clavien-Dindo grading (CDG), and occurrence of a complication was defined as any deviation from CDG 0.The Clavien-Dindo grading system is a classification of surgical complications: Grad 0 signifying no complication, Grade I identifying complications with any deviation from the normal intra- or postoperative course requiring medical treatment, and so forth. Detailed definitions are provided in the Excel spreadsheet. Surgery-related as well as none-surgery-related complications are counted. In case of multiple complications, only the complication with the highest CDG was counted per patient.

Input Feature Definitions All features are measured preoperatively. Recorded baseline variables will include age, gender, maximum aneurysm diameter, anatomical location (artery), total number of aneurysms per patient, if multiple aneurysms were treated during the index session, calcification of the aneurysm wall or neck, aneurysm morphology (saccular, dissecting, fusiform, or other), involvement of critical perforating or branch vessels, and intraluminal thrombosis.

In addition, the investigators will capture prior SAH, mRS at admission, prior aneurysm treatment, presence of anticoagulation/antiplatelet therapy preoperatively, and hypertension, as well as American Society of Anesthesiologists (ASA) grading, the PHASES, ELAPSS, and UIATS scores including the UIATS "pro-repair" and "pro-conservative treatment" subscores. The unruptured intracranial aneurysm treatment score (UIATS) consists of two subscores: One that represents the strength of recommendation for invasive repair of an unruptured aneurysm, and one that represents the strength of recommendation for conservative management of an unruptured aneurysm. The final overall UIATS score is subsequently calculated as the difference between the two subscores. Also included was the surgical approach: minimally invasive or standard approach, and whether a bypass was performed.

Conditions
Aneurysm, Brain
Being tested
Microsurgery
Keywords
machine learning, unruptured aneurysm
Medical subject headings
Intracranial Aneurysm

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MicrosurgeryProcedure or surgery

    Microsurgery for unruptured intracranial aneurysm

Study groups in NCT04819074
Study groupRoleWhat they receive
Patients with unruptured brain aneurysmsWe will include all adult patients (18 years or older) undergoing microsurgical treatment for UIAs. No specific exclusion criteria will be set. Patients with prior SAH may only be included when surgical treatment occurred at least 4 weeks after ictus. Only patients treated from January 1st 2010 onwards can be included in this study. No intervention.
Receives: Procedure: Microsurgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. modified Rankin Scale

    Neurological outcome was assessed by the modified Rankin scale (mRS), and a favorable neurological outcome was defined as mRS 0, 1, or 2. The scale runs from 0 to 5, and higher scores mean a worse outcome.

    Measured: Within 24 hours of admission to discharge, assessed up to 30 days

  2. Sensorimotor neurological deficits

    Any new sensorimotor neurological deficits after surgery will be captured.

    Measured: Within 24 hours of admission to discharge, assessed up to 30 days

  3. Clavien Dindo Complication Grading

    Complications will be assessed using the modified 2009 Clavien-Dindo grading (CDG), and occurrence of a complication was defined as any deviation from CDG 0. The CDG runs from 0 to 5, and higher scores mean a worse complication.

    Measured: Within 24 hours of admission to discharge, assessed up to 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Mar 2021
  2. Study start20 May 2021
  3. Primary completion1 Jan 2022 (estimated)
  4. Study completion1 Oct 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
4,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04819074
Sponsor's protocol ID
PRAEMIUM
Acronym
PRAEMIUM
Status last verified
Dec 2021
First submitted
18 Mar 2021
Last updated
21 Dec 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Staartjes VE, Adamides AA, Anania P, Baskaya MK, Benes V, Dehdashti AR, Di Ieva A, Ferroli P, Jakola AS, Lanzino G, Lawton MT, Petr O, Petutschnigg T, Pinna G, Podlesek D, Radovanovic I, Rohde V, Stroh-Holly N, Sturiale CL, Wang AC, Regli L, Esposito G; PRAEMIUM investigators. Contemporary adverse event profile of microsurgery for intracranial unruptured aneurysms in high-volume microsurgical centers: the international PRAEMIUM study. Neurosurg Focus. 2025 Dec 1;59(6):E18. doi: 10.3171/2025.9.FOCUS25723.

    PubMed 41343785

Questions about this trial

What is this clinical trial studying?

An observational study of Aneurysm, Brain, run by University of Zurich at 37 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 37 sites in United States, Italy, Germany, Netherlands, Australia and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Victor Staartjes (+41 44 255 2660, praemium@usz.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

modified Rankin Scale (time frame: Within 24 hours of admission to discharge, assessed up to 30 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04819074, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in